|
Market Cap (13-Jul) $6,957,488 (1,468th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 582,113 |
Shortsold (6-Dec) 611,822 (0.21%) (374th) |
|
52w High $0.079 |
52w Low $0.015 |
P/E - |
EPS -0.02 |
ACR released this announcement to the ASX on 26 August 2022, 9:14. The announcement is not marked as price sensitive, and is 26 page(s) in length and 497.87kb in size.
You can view all announcements from ACR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACR was 0.004% short sold according to ASIC data. It was ranked the 605th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).
| Other Recent Announcements from ACR | |
|---|---|
| Appendix 3Y Brooke | 16 June 2023, 9:27 |
| Application for quotation of securities - ACR | 16 June 2023, 9:25 |
| 4th FDA ANDA approval received - Dapsone Gel, 5% | 7 June 2023, 10:35 |
| Appendix 4G and Corporate Governance Statement | 26 August 2022, 9:14 |
| Appendix 4E and FY22 Annual Report | 26 August 2022, 9:12 |
| Acrux's sixth generic dossier accepted by FDA for review | 8 August 2022, 9:33 |
| Updated Corporate Policy - Code of Conduct | 28 June 2022, 12:14 |
You must be logged in to post a reply.
